FDA-TRACK: Biosimilar User Fee Act Procedural Notification Goals Summary
Similar Posts
Naturich Cosmetique Labs – 713565 – 09/25/2025
CGMP/Finished Pharmaceuticals/AdulteratedInnovative Science and Technology Approaches for New Drugs (ISTAND) Program Submission Process
The 21st Century Cures Act formally established a multi-step process for Drug Development Tools (DDT) qualification. Qualification of a DDT is for a specific context of use (COU), and the qualified DDT may be used for the COU by any person in drug or biologics development.Shiva Analyticals Private Limited – 707857 – 07/23/2025
CGMP/Finished Pharmaceuticals/AdulteratedCommissioner’s National Priority Voucher (CNPV) Pilot Program
FDA Commissioner’s National Priority Voucher Program. The Commissioner’s National Priority Voucher Program offers an unprecedented opportunity to reduce drug and biologic review times from 10-12 months to just 1-2 months.Completed PDUFA VI Deliverables
Completed PDUFA VI DeliverablesFDA approves mitomycin intravesical solution for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer
On June 12, 2025, the Food and Drug Administration approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).